SAINT CLOUD, Minn. - April 25, 2022 - Microbiologics, the foremost provider of biomaterials and contract microbiology research services, is pleased to announce the acquisition of Cryologics, a leader in cryopreservation of environmental isolates for use as quality control microorganisms. The procurement of Cryologics extends Microbiologics' capacity to serve QC microbiologists dedicated to the safety of pharmaceutical and personal care products.
WILMINGTON, N.C., April 21, 2022 - The PPD clinical research business of Thermo Fisher Scientific was named "Best Contract Research Organization" at the 15th annual Vaccine Industry Excellence (ViE) Awards during the 2022 World Vaccine Congress, recognizing its success in helping customers develop safe and effective vaccines to improve health and save lives.
$44 million facility increases production of single-use bioprocess containers that are critical to the development of new vaccines and therapies
-- Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies
Chicago, IL (April 14, 2022) – Advanced Clinical, a clinical development and strategic resourcing organization, is pleased to announce its continued expansion into Europe with the opening of a new office in Zug, Switzerland.
Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma, as well as produce gene therapy product for current and future clinical trials.
Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19
Paris, April 4, 2022. Sanofi launches today its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors. Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand.
- Abbott and LISC invest more than $37 million to empower and grow diverse small businesses that provide manufacturing and essential products for healthcare companies
Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease
